Still debating sentinel lymph node biopsy?

Dermatology Online Journal

Volumn 7, Issue 2, 2001, Pages

  Burrall, Barbara ^a   Khatri, Vijay ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; GANGLIOSIDE GM2;

ACCURACY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; ELECTIVE SURGERY; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MELANOMA; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; SENTINEL LYMPH NODE BIOPSY; TUMOR VOLUME; METASTASIS; PATHOLOGY; STANDARD; UTILIZATION REVIEW;

HUMANS; MELANOMA; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY;

EID: 3943062165     PISSN: 10872108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Koh HK, Geller AC, Miller DR, Davis BB, Lew RA. Skin cancer: prevention and control. In: Greenwald P, Kramer BS, Weed DL, eds. Cancer Prevention and control. New York; Marcel Dekker, 1995:611-40.
2. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51(1):15-36. PubMed
3. Chang AE, Karnell LH, Menck HR. The national cancer database report on cutaneous and non-cutaneous melanoma: a summary of 84,836 cases from the past decade. Cancer 1998;8:1664-78.
4. Rigel DS, Friedman RJ, Kopf AW. The incidence of malignant melanoma in the United States: issues as we approach the 21st century. J Am Acad Dermatol 1996;34(5 Pt 1):839-47. PubMed
5. Johnson TM, Chang A, Redman B, Rees R, Bradford C, Riba M, Lowe L. Management of melanoma with a multidisciplinary melanoma clinic model. J Am Acad Dermatol 2000;42:820-6.
6. Kanzler MH, Mraz-Gernhard S. Primary cutaneous malignant melanoma and its precursor lesions: diagnostic and therapeutic overview. J Am Acad Dermatol 2001;45(2):260-76. PubMed
7. Reintgen D, Cruse CW, Wells K, Berman C, Fenske N, Glass F, Schroer K, Heller R, Ross M, Lyman G. The orderly progression of melanoma nodal metastases. Ann Surg 1994;220:759-67.
8. Thompson JF, McCarthy WH, Bosch CMJ, O'Brien CJ, Quinn MJ, Paramaesvaran S, Crotty K, McCarthy SW, Uren RF, Howman-Giles R. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 1995;5:255-260.
9. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH, Lee JJ, Balch CM, Reintgen DS, Ross MI. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17(3):976-83. PubMed
10. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, Foshag LJ, Cochran AJ. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127(4):392-9. PubMed
11. Wrone DA, Tanabe KK, Cosimi B, Gadd MA, Souba WW, Sober AJ. Lymphedema after sentinel lymph node biopsy for cutaneous melanoma. Arch Dermatol 2000;136:511-4.
12. McMasters KM, Reintgen DS, Ross MI, Gershenwald JE, Edwards MJ, Sober A, Fenske N, Glass F, Balch CM, Coit DG. Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. J Clin Oncol 2001;19(11):2851-5. PubMed
13. Balch CM, Soong SJ, Bartolucci AA, Urist MM, Karakousis CP, Smith TJ, Temple WJ, Ross MI, Jewell WR, Mihm MC, Barnhill RL, Wanebo HJ. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996;224(3):255-63; discussion 263-6. PubMed
14. Balch CM, Soong S, Ross MI, Urist MM, Karakousis CP, Temple WJ, Mihm MC, Barnhill RL, Jewell WR, Wanebo HJ, Harrison R. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 2000;7(2):87-97. PubMed
15. Cherpelis BS, Haddad F, Messina J, Cantor AB, Fitzmorris K, Reintgen DS, Fenske N, Glass LF. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas. J Am Acad Dermatol 2001;44:762-6.
16. Acland KM, Calonje HE, O'Doherty M, Numan T, Page C, Higgins E, Russell-Jones R. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol 2001;19:2674-78.
17. Joseph E, Brobeil BA, Glass F, Glass J, Messina J, DeConti R, Cruse W, Rapaport DP, Berman C, Fenske N, Reintgen DS. Ann Surg Onc 1998;5(2):119-25.
18. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, Liu PY, Lyman GH, Morabito A. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19(16):3622-34. PubMed
19. Sim FH, Taylor WJ, Pritchard DJ, Soule EH. Lymphadenectomy in the management of stage I malignant melanoma: p prospective randomized study. Mayo Clin Proc 1986;62:697-705.
20. Veronesi U, Adamus J, Bandiera DC, Brennhovd O, Caceres E, Cascinelli N, Claudio F, Ikonopisor RL, Javorski VV, Dirov S, Kulakowski A, Lacour J, Lejeune F, Mechl Z, Morabito A, Rode I, Sergeev S, van Slooten E, Szczygiel K, Trapeznikov NN, Wagner RI. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 1982;49:2420-30.
21. Norman J, Cruse CW, Wells K, Berman C, Clark R, Reintgen DS. A redefinition of skin lymphatic drainage by lymphoscintigraphy for malignant melanoma. Am J Surg 1991;162:432-7.
22. Balch CM. The John Wayne Clinical Research Lecture. Surgical management of melanoma: results of prospective randomized trials. Ann Surg Oncol 1998;5(4):301-9. PubMed
23. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 1998;351(9105):793-6. PubMed
24. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14(1):7-17. PubMed
25. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18(12):2444-58. PubMed
26. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, Rao U. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19(9):2370-80. PubMed
27. Dubois RW, Swetter SM, Atkins M, McMasters K, Halbert R, Miller SJ, Shiell R, Kirkwood J. Developing indications for the use of sentinel lymph node biopsy and adjuvant high-dose interferon alfa-2b in melanoma. Arch Dermatol 2001;137(9):1217-24. PubMed
28. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton Jr A, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-48.